-
1
-
-
39149084101
-
Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies
-
Endogenous Hormones and Prostate Cancer Collaborative Group
-
Endogenous Hormones and Prostate Cancer Collaborative Group RoddamAW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 170-183
-
-
Roddam, A.W.1
Allen, N.E.2
Appleby, P.3
Key, T.J.4
-
2
-
-
57649176913
-
Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth
-
Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-20.
-
(2009)
Eur Urol
, vol.55
, pp. 310-320
-
-
Morgentaler, A.1
Traish, A.M.2
-
3
-
-
33644601865
-
Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer
-
San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006;175:1341-5.
-
(2006)
J Urol
, vol.175
, pp. 1341-1345
-
-
San Francisco, I.F.1
Regan, M.M.2
Dewolf, W.C.3
Olumi, A.F.4
-
4
-
-
41749098807
-
The ratio of serum testosterone to prostate specific antigen predicts prostate cancer in hypogonadal men
-
Rhoden EL, Riedner CL, Morgentaler A. The ratio of serum testosterone to prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008;179:1741-5.
-
(2008)
J Urol
, vol.179
, pp. 1741-1745
-
-
Rhoden, E.L.1
Riedner, C.L.2
Morgentaler, A.3
-
5
-
-
27744467589
-
Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer
-
DOI 10.1097/01.ju.0000181818.51977.29
-
Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005;174:2178-80. (Pubitemid 41611769)
-
(2005)
Journal of Urology
, vol.174
, Issue.6
, pp. 2178-2180
-
-
Teloken, C.1
Teodosio, D.R.C.2
Caraver, F.3
Weber, F.A.4
Cavalheiro, A.P.5
Graziottin, T.M.6
-
6
-
-
0344406150
-
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
-
DOI 10.1097/01.ju.0000062674.43964.d0
-
Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003;169:1670-5. (Pubitemid 36443468)
-
(2003)
Journal of Urology
, vol.169
, Issue.5
, pp. 1670-1675
-
-
Massengill, J.C.1
Sun, L.2
Moul, J.W.3
Wu, H.4
McLeod, D.G.5
Amling, C.6
Lance, R.7
Foley, J.8
Sexton, W.9
Kusuda, L.10
Chung, A.11
Soderdahl, D.12
Donahue, T.13
-
7
-
-
13844299328
-
Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy
-
DOI 10.1016/j.eururo.2004.11.003
-
Imamoto T, Suzuki H, Fukasawa S, Shimbo M, Inahara M, Komiya A, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005;47:308-12. (Pubitemid 40248848)
-
(2005)
European Urology
, vol.47
, Issue.3
, pp. 308-312
-
-
Imamoto, T.1
Suzuki, H.2
Fukasawa, S.3
Shimbo, M.4
Inahara, M.5
Komiya, A.6
Ueda, T.7
Shiraishi, T.8
Ichikawa, T.9
-
8
-
-
18744369944
-
Testosterone as a predictor of pathological stage in clinically localized prostate cancer
-
DOI 10.1097/01.ju.0000158040.33531.e7
-
Isom-Batz G, Bianco FJ Jr, KattanMW,Mulhall JP, Lilja H, EasthamJA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173:1935-7. (Pubitemid 40675215)
-
(2005)
Journal of Urology
, vol.173
, Issue.6
, pp. 1935-1937
-
-
Isom-Batz, G.1
Blanco Jr., F.J.2
Kattan, M.W.3
Mulhall, J.P.4
Lilja, H.5
Eastham, J.A.6
-
9
-
-
77649247662
-
Serum testosterone is associated with aggressive prostate cancer in older men: Results from the Baltimore Longitudinal Study of Aging
-
Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 2010;105:824-9.
-
(2010)
BJU Int
, vol.105
, pp. 824-829
-
-
Pierorazio, P.M.1
Ferrucci, L.2
Kettermann, A.3
Longo, D.L.4
Metter, E.J.5
Carter, H.B.6
-
10
-
-
34547156657
-
Preoperative Serum Testosterone Level as an Independent Predictor of Treatment Failure following Radical Prostatectomy
-
DOI 10.1016/j.eururo.2007.03.052, PII S0302283807004289
-
Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007;52:696-701. (Pubitemid 47126163)
-
(2007)
European Urology
, vol.52
, Issue.3
, pp. 696-701
-
-
Yamamoto, S.1
Yonese, J.2
Kawakami, S.3
Ohkubo, Y.4
Tatokoro, M.5
Komai, Y.6
Takeshita, H.7
Ishikawa, Y.8
Fukui, I.9
-
11
-
-
84857033892
-
Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer
-
Røder MA, Christensen IJ, Berg KD, Gruschy L, Brasso K, Iversen P. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int 2012;109:520-4.
-
(2012)
BJU Int
, vol.109
, pp. 520-524
-
-
Røder, M.A.1
Christensen, I.J.2
Berg, K.D.3
Gruschy, L.4
Brasso, K.5
Iversen, P.6
-
12
-
-
3042760475
-
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: Cancer patients treated with radical prostatectomy
-
DOI 10.1097/00000478-200407000-00013
-
Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928-34. (Pubitemid 38856850)
-
(2004)
American Journal of Surgical Pathology
, vol.28
, Issue.7
, pp. 928-934
-
-
Li, R.1
Wheeler, T.2
Dai, H.3
Frolov, A.4
Thompson, T.5
Ayala, G.6
-
13
-
-
0026021087
-
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
-
for the Zoladex Study Group
-
Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA for the Zoladex Study Group. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 1991;265:618-21.
-
(1991)
JAMA
, vol.265
, pp. 618-621
-
-
Chodak, G.W.1
Vogelzang, N.J.2
Caplan, R.J.3
Soloway, M.4
Smith, J.A.5
-
14
-
-
33645459812
-
Circulating steroid hormones and the risk of prostate cancer
-
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
-
(2006)
Cancer Epidemiol Biomarkers Prev
, vol.15
, pp. 86-91
-
-
Severi, G.1
Morris, H.A.2
MacInnis, R.J.3
English, D.R.4
Tilley, W.5
Hopper, J.L.6
-
15
-
-
48849111874
-
Development of a nomogram for predicting high-grade prostate cancer on biopsy: The significance of serum testosterone levels
-
Ide H, Yasuda M, Nishio K, Saito K, Isotani S, Kamiyama Y, et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res 2008;28:2487-92.
-
(2008)
Anticancer Res
, vol.28
, pp. 2487-2492
-
-
Ide, H.1
Yasuda, M.2
Nishio, K.3
Saito, K.4
Isotani, S.5
Kamiyama, Y.6
-
16
-
-
67349282280
-
Testosterone and prostate cancer: Revisiting old paradigms
-
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.
-
(2009)
Eur Urol
, vol.56
, pp. 48-56
-
-
Isbarn, H.1
Pinthus, J.H.2
Marks, L.S.3
Montorsi, F.4
Morales, A.5
Morgentaler, A.6
-
17
-
-
80052744918
-
High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone
-
Botto H, Neuzillet Y, Lebret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol 2011;186:1400-5.
-
(2011)
J Urol
, vol.186
, pp. 1400-1405
-
-
Botto, H.1
Neuzillet, Y.2
Lebret, T.3
Camparo, P.4
Molinie, V.5
Raynaud, J.P.6
-
18
-
-
79960258328
-
Preoperative hypogonadism is not an independent predictor of highrisk disease in patients undergoing radical prostatectomy
-
Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of highrisk disease in patients undergoing radical prostatectomy. Cancer 2011;117:3953-62.
-
(2011)
Cancer
, vol.117
, pp. 3953-3962
-
-
Salonia, A.1
Gallina, A.2
Briganti, A.3
Abdollah, F.4
Suardi, N.5
Capitanio, U.6
-
19
-
-
33745213399
-
Hypogonadism in male patients with cancer
-
Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer 2006;106:2583-91.
-
(2006)
Cancer
, vol.106
, pp. 2583-2591
-
-
Garcia, J.M.1
Li, H.2
Mann, D.3
Epner, D.4
Hayes, T.G.5
Marcelli, M.6
-
20
-
-
33847163949
-
The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy
-
Heracek J, Urban M, Sachova J, Kuncova J, Eis V, Mandys V, et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett 2007;28:45-51. (Pubitemid 46291146)
-
(2007)
Neuroendocrinology Letters
, vol.28
, Issue.1
, pp. 45-51
-
-
Heracek, J.1
Urban, M.2
Sachova, J.3
Kuncova, J.4
Eis, V.5
Mandys, V.6
Hampl, R.7
Starka, L.8
-
21
-
-
58649101843
-
Absence of relationship between steroid hormone levels and prostate cancer tumor grade
-
Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 2009;73:356-61.
-
(2009)
Urology
, vol.73
, pp. 356-361
-
-
Sher, D.J.1
Mantzoros, C.2
Jacobus, S.3
Regan, M.M.4
Lee, G.S.5
Oh, W.K.6
-
22
-
-
58849083630
-
The evolving role of oestrogens and their receptors in the development and progression of prostate cancer
-
Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009;55:533-542.
-
(2009)
Eur Urol
, vol.55
, pp. 533-542
-
-
Bonkhoff, H.1
Berges, R.2
-
23
-
-
80054756183
-
Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy
-
Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, et al. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 2011;117:5029-38.
-
(2011)
Cancer
, vol.117
, pp. 5029-5038
-
-
Salonia, A.1
Gallina, A.2
Briganti, A.3
Suardi, N.4
Capitanio, U.5
Abdollah, F.6
-
24
-
-
79954498385
-
Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy
-
Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, et al. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU Int 2011;107:1243-9.
-
(2011)
BJU Int
, vol.107
, pp. 1243-1249
-
-
Salonia, A.1
Gallina, A.2
Briganti, A.3
Suardi, N.4
Capitanio, U.5
Abdollah, F.6
-
25
-
-
79952253824
-
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
-
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
-
(2011)
Eur Urol
, vol.59
, pp. 572-583
-
-
Mottet, N.1
Bellmunt, J.2
Bolla, M.3
Joniau, S.4
Mason, M.5
Matveev, V.6
-
26
-
-
84863300695
-
National Comprehensive Cancer Network practice guidelines 2011
-
[cited 2011 Jul 23]. Available from
-
National Comprehensive Cancer Network practice guidelines 2011. Prostate cancer. [cited 2011 Jul 23]. Available from: http://www.nccn.org/professionals/ physician-gls/pdf/prostate.pdf.
-
Prostate Cancer
-
-
-
27
-
-
0142134377
-
-
6th ed. New York: Springer
-
Green F, Page D, Fleming I, Fritz A, Balch CM, Haller DG, et al. American Joint Committee on cancer staging manual. 6th ed. New York: Springer; 2002.
-
(2002)
American Joint Committee on Cancer Staging Manual
-
-
Green, F.1
Page, D.2
Fleming, I.3
Fritz, A.4
Balch, C.M.5
Haller, D.G.6
-
28
-
-
3042692259
-
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update
-
American Association of Clinical Endocrinologists
-
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract 2002;8:440-56.
-
(2002)
Endocr Pract
, vol.8
, pp. 440-456
-
-
Petak, S.M.1
Nankin, H.R.2
Spark, R.F.3
Swerdloff, R.S.4
Rodriguez-Rigau, L.J.5
-
29
-
-
56249088599
-
Investigation, treatment, and monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations
-
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009;55:121-30.
-
(2009)
Eur Urol
, vol.55
, pp. 121-130
-
-
Wang, C.1
Nieschlag, E.2
Swerdloff, R.3
Behre, H.M.4
Hellstrom, W.J.5
Gooren, L.J.6
-
30
-
-
77950874403
-
Tutorial in biostatistics: Dose-response analyses using restricted cubic spline functions in public health research
-
Desquilbet L, Mariotti F. Tutorial in biostatistics: dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010;29:1037-57.
-
(2010)
Stat Med
, vol.29
, pp. 1037-1057
-
-
Desquilbet, L.1
Mariotti, F.2
-
31
-
-
0029020424
-
Dose-response and trend analysis in epidemiology: Alternatives to categorical analysis
-
Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995;6:356-65.
-
(1995)
Epidemiology
, vol.6
, pp. 356-365
-
-
Greenland, S.1
-
32
-
-
23844474746
-
Correlates of circulating androgens in mid-life women: The Study of Women's Health Across the Nation
-
DOI 10.1210/jc.2004-2063
-
Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health across the Nation. J Clin Endocrinol Metab 2005;90:4836-45. (Pubitemid 41159380)
-
(2005)
Journal of Clinical Endocrinology and Metabolism
, vol.90
, Issue.8
, pp. 4836-4845
-
-
Santoro, N.1
Torrens, J.2
Crawford, S.3
Allsworth, J.E.4
Finkelstein, J.S.5
Gold, E.B.6
Korenman, S.7
Lasley, W.L.8
Luborsky, J.L.9
McConnell, D.10
Sowers, M.F.11
Weiss, G.12
-
33
-
-
77951642063
-
Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study
-
Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010;95:1810-8.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 1810-1818
-
-
Tajar, A.1
Forti, G.2
O'Neill, T.W.3
Lee, D.M.4
Silman, A.J.5
Finn, J.D.6
-
34
-
-
70349229310
-
Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy
-
Ellem SJ, Wang H, Poutanen M, Risbridger GP. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol 2009;175:1187-99.
-
(2009)
Am J Pathol
, vol.175
, pp. 1187-1199
-
-
Ellem, S.J.1
Wang, H.2
Poutanen, M.3
Risbridger, G.P.4
-
35
-
-
77950363332
-
Aromatase and regulating the estrogen: Androgen ratio in the prostate gland
-
Ellem SJ, Risbridger GP. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010;118:246-51.
-
(2010)
J Steroid Biochem Mol Biol
, vol.118
, pp. 246-251
-
-
Ellem, S.J.1
Risbridger, G.P.2
-
36
-
-
79951989027
-
Impact of age at diagnosis on prostate cancer treatment and survival
-
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235-41.
-
(2011)
J Clin Oncol
, vol.29
, pp. 235-241
-
-
Bechis, S.K.1
Carroll, P.R.2
Cooperberg, M.R.3
-
37
-
-
80255140736
-
Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of Radiation Therapy Oncology Group Trials
-
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, et al. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of Radiation Therapy Oncology Group Trials. Int J Radiat Oncol Biol Phys 2011;81:1293-301.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.81
, pp. 1293-1301
-
-
Hamstra, D.A.1
Bae, K.2
Pilepich, M.V.3
Hanks, G.E.4
Grignon, D.J.5
McGowan, D.G.6
-
38
-
-
34250745251
-
Obesity and Prostate Cancer: Epidemiology and Clinical Implications
-
DOI 10.1016/j.eururo.2007.04.069, PII S0302283807006641
-
Buschemeyer WC III, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331-43. (Pubitemid 46963472)
-
(2007)
European Urology
, vol.52
, Issue.2
, pp. 331-343
-
-
Buschemeyer III, W.C.1
Freedland, S.J.2
-
39
-
-
1442265961
-
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy
-
DOI 10.1200/JCO.2004.03.132
-
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45. (Pubitemid 41079772)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.3
, pp. 439-445
-
-
Amling, C.L.1
Riffenburgh, R.H.2
Sun, L.3
Moul, J.W.4
Lance, R.S.5
Kusuda, L.6
Sexton, W.J.7
Soderdahl, D.W.8
Donahue, T.F.9
Foley, J.P.10
Chung, A.K.11
McLeod, D.G.12
-
40
-
-
70249099520
-
Obese men have higher-grade and larger tumors: An analysis of the duke prostate center database
-
Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009;12:259-63.
-
(2009)
Prostate Cancer Prostatic Dis
, vol.12
, pp. 259-263
-
-
Freedland, S.J.1
Bañez, L.L.2
Sun, L.L.3
Fitzsimons, N.J.4
Moul, J.W.5
-
41
-
-
33646793000
-
Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women
-
DOI 10.1016/j.jsbmb.2006.02.004, PII S0960076006000598
-
Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006;99: 182-8. (Pubitemid 43766081)
-
(2006)
Journal of Steroid Biochemistry and Molecular Biology
, vol.99
, Issue.4-5
, pp. 182-188
-
-
Labrie, F.1
Belanger, A.2
Belanger, P.3
Berube, R.4
Martel, C.5
Cusan, L.6
Gomez, J.7
Candas, B.8
Castiel, I.9
Chaussade, V.10
Deloche, C.11
Leclaire, J.12
-
42
-
-
33947363367
-
Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer
-
DOI 10.1016/j.steroids.2007.01.004, PII S0039128X07000293
-
Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 2007;72:375-80. (Pubitemid 46452717)
-
(2007)
Steroids
, vol.72
, Issue.4
, pp. 375-380
-
-
Heracek, J.1
Richard, H.2
Martin, H.3
Luboslav, S.4
Jana, S.5
Jitka, K.6
Vaclav, E.7
Michael, U.8
Vaclav, M.9
-
43
-
-
0842311632
-
The Androgen Axis in Recurrent Prostate Cancer
-
DOI 10.1158/1078-0432.CCR-1146-03
-
Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8. (Pubitemid 38173980)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.2
, pp. 440-448
-
-
Mohler, J.L.1
Gregory, C.W.2
Ford III, H.3
Kim, D.4
Weaver, C.M.5
Petrusz, P.6
Wilson, E.M.7
French, F.S.8
-
44
-
-
27644452640
-
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
-
DOI 10.1158/1078-0432.CCR-05-0525
-
Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7. (Pubitemid 41557182)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.13
, pp. 4653-4657
-
-
Titus, M.A.1
Schell, M.J.2
Lih, F.B.3
Tomer, K.B.4
Mohler, J.L.5
-
45
-
-
80052846905
-
Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone
-
Mohler JL, TitusMA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011;17:5844-9.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5844-5849
-
-
Mohler, J.L.1
Titus, M.A.2
Wilson, E.M.3
-
46
-
-
33750486196
-
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - Results from a 4-month pre-radical prostatectomy study
-
DOI 10.1002/pros.20499
-
Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer - results from a 4-month pre-radical prostatectomy study. Prostate 2006;66:1674-85. (Pubitemid 44646358)
-
(2006)
Prostate
, vol.66
, Issue.15
, pp. 1674-1685
-
-
Gleave, M.1
Qian, J.2
Andreou, C.3
Pommerville, P.4
Chin, J.5
Casey, R.6
Steinhoff, G.7
Fleshner, N.8
Bostwick, D.9
Thomas, L.10
Rittmaster, R.11
-
47
-
-
76749096777
-
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: Implications for prostate cancer chemoprevention
-
Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, et al. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res 2010;70:1286-95.
-
(2010)
Cancer Res
, vol.70
, pp. 1286-1295
-
-
Mostaghel, E.A.1
Geng, L.2
Holcomb, I.3
Coleman, I.M.4
Lucas, J.5
True, L.D.6
-
48
-
-
0037812658
-
The influence of finasteride on the development of prostate cancer
-
DOI 10.1056/NEJMoa030660
-
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.3
, pp. 215-224
-
-
Thompson, I.M.1
Goodman, P.J.2
Tangen, C.M.3
Lucia, M.S.4
Miller, G.J.5
Ford, L.G.6
Lieber, M.M.7
Cespedes, R.D.8
Atkins, J.N.9
Lippman, S.M.10
Carlin, S.M.11
Ryan, A.12
Szczepanek, C.M.13
Crowley, J.J.14
Coltman Jr., C.A.15
-
49
-
-
77950498003
-
Effect of dutasteride on the risk of prostate cancer
-
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
-
(2010)
N Engl J Med
, vol.362
, pp. 1192-1202
-
-
Andriole, G.L.1
Bostwick, D.G.2
Brawley, O.W.3
Gomella, L.G.4
Marberger, M.5
Montorsi, F.6
-
50
-
-
84859108456
-
Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial
-
Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1103-11
-
(2012)
Lancet
, vol.379
, pp. 1103-1111
-
-
Fleshner, N.E.1
Lucia, M.S.2
Egerdie, B.3
Aaron, L.4
Eure, G.5
Nandy, I.6
|